Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV002271817 | SCV002555819 | likely pathogenic | Cobalamin C disease | 2024-03-25 | criteria provided, single submitter | clinical testing | Variant summary: ABCD4 c.1295G>A (p.Arg432Gln) results in a conservative amino acid change located in the ABC transporter-like, ATP-binding domain (IPR003439) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 251442 control chromosomes. c.1295G>A has been reported in the literature as a compound heterozygous genotype in at-least two individuals affected with Methylmalonic Acidemia With Homocystinuria (example, Fettelschoss_2017 cited by Liu_2019, Pillai_2019). At least one publication reports experimental evidence evaluating an impact on protein function (Fettelschoss_2017). The most pronounced variant effect results in decreased interaction of ABCD4 with its binding partner LMBD1. The following publications have been ascertained in the context of this evaluation (PMID: 28572511, 33845046, 30651581, 33729671). ClinVar contains an entry for this variant (Variation ID: 1698540). Based on the evidence outlined above, the variant was classified as likely pathogenic. |
Fulgent Genetics, |
RCV005008502 | SCV005635714 | likely pathogenic | Methylmalonic acidemia with homocystinuria, type cblJ | 2024-05-04 | criteria provided, single submitter | clinical testing |